New vaccine technologies to combat outbreak situations

Frontiers in Immunology

Volumn 9, Issue SEP, 2018, Pages

  Rauch, Susanne ^a   Jasny, Edith ^a   Schmidt, Kim E ^a   Petsch, Benjamin ^a  

^a CureVac GmbH   (Germany)

Author keywords

DNA vaccine; MRNA vaccine; Pandemics; Vaccine development; Viral vector vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; MESSENGER RNA VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

DRUG DELIVERY SYSTEM; DRUG MECHANISM; EBOLAVIRUS; EPIDEMIC; GLOBAL HEALTH; HUMAN; LARGE SCALE PRODUCTION; MEASLES VIRUS; NONHUMAN; PANDEMIC; REVIEW; TECHNOLOGY; VESICULOVIRUS; ANIMAL; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; IMMUNOLOGY; PROCEDURES; VACCINATION;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISEASE OUTBREAKS; GLOBAL HEALTH; HUMANS; VACCINATION; VACCINES;

EID: 85054450858     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01963     Document Type: Review

References (181)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. (2002) 76: 105-15. Doi: 10.1353/bhm.2002.0022
2. Drosten C, Gunther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. (2003) 348: 1967-76. Doi: 10.1056/NEJMoa030747
3. Fouchier RA, Kuiken T, Schutten M, Van Amerongen G, Van Doornum GJ, Van Den Hoogen BG, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature (2003) 423: 240. Doi: 10.1038/423240a
4. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. (2003) 349: 2431-41. Doi: 10.1056/NEJMra032498
5. Reperant LA, Osterhaus A. AIDS, Avian flu, SARS, MERS, Ebola, Zika... What next? Vaccine (2017) 35: 4470-4. Doi: 10.1016/j.vaccine.2017.04.082
6. Olival KJ, Hayman DT. Filoviruses in bats: current knowledge and future directions. Viruses (2014) 6: 1759-88. Doi: 10.3390/v6041759
7. Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. (2017) 17: 1276-84. Doi: 10.1016/S1473-3099(17)30541-8
8. Dick GW. Epidemiological notes on some viruses isolated in Uganda; Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda, S., and Zika viruses. Trans R Soc Trop Med Hyg. (1953) 47: 13-48. Doi: 10.1016/0035-9203(53)90021-2
9. Palacios R, Poland GA, Kalil J. Another emerging arbovirus, another emerging vaccine: targeting Zika virus. Vaccine (2016) 34: 2291-3. Doi: 10.1016/j.vaccine.2016.03.059
10. Morabito KM, Graham BS. Zika virus vaccine development. J Infect Dis. (2017) 216: S957-63. Doi: 10.1093/infdis/jix464
11. Halstead SB. Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Hum Vaccin Immunother. (2018) doi: 10.1080/21645515.2018.1445448. [Epub ahead of print].
12. Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent advances in Ebolavirus vaccine development. Hum Vaccin. (2010) 6: 439-49. Doi: 10.4161/hv.6.6.11097
13. Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. (2015) 23: 189-95. Doi: 10.1128/CVI.00609-15
14. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS ONE (2013) 8: e57755. Doi: 10.1371/journal.pone.0057755
15. Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing-An overview. Vaccine (2017) 35: 4064-71. Doi: 10.1016/j.vaccine.2017.06.003
16. Mclean KA, Goldin S, Nannei C, Sparrow E, Torelli G. The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine (2016) 34: 5410-3. Doi: 10.1016/j.vaccine.2016.08.019
17. Gilbert JA. Seasonal and pandemic influenza: global fatigue versus global preparedness. Lancet Respir Med. (2018) 6: 94-5. Doi: 10.1016/S2213-2600(17)30466-6
18. Loomis RJ, Johnson PR. Emerging vaccine technologies. Vaccines (2015) 3: 429-47. Doi: 10.3390/vaccines3020429
19. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA. (2014) 111: 12288-93. Doi: 10.1073/pnas.1402981111
20. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med. (2013) 368: 551-60. Doi: 10.1056/NEJMra1204186
21. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. Accelerating next-generation vaccine development for global disease prevention. Science (2013) 340: 1232910. Doi: 10.1126/science.1232910
22. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. (2009) 157: 153-65. Doi: 10.1038/bjp.2008.349
23. Ramezanpour B, Haan I, Osterhaus A, Claassen E. Vector-based genetically modified vaccines: exploiting Jenner's legacy. Vaccine (2016) 34: 6436-48. Doi: 10.1016/j.vaccine.2016.06.059
24. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. (2017) 4: 43-63. Doi: 10.1016/j.gendis.2017.04.001
25. Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. (2013) 13: 421-33. Doi: 10.2174/1566523213666131125095046
26. Lauer KB, Borrow R, Blanchard TJ. Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol. (2017) 24: e00298-16. Doi: 10.1128/CVI.00298-16
27. Afkhami S, Yao Y, Xing Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev. (2016) 3: 16030. Doi: 10.1038/mtm.2016.30
28. + T cells induced by different adenovirus vectors. J Virol. (2013) 87: 1359-72. Doi: 10.1128/JVI.02055-12
29. Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology (2018) 153: 1-9. Doi: 10.1111/imm.12829
30. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. (2014) 10: 2875-84. Doi: 10.4161/hv.29594
31. O'hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. (2012) 205: 772-81. Doi: 10.1093/infdis/jir850
32. Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann Intern Med (2016) 164: 313-22. Doi: 10.7326/M15-0880
33. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, et al. Attenuated measles virus as a vaccine vector. Vaccine (2007) 25: 2974-83. Doi: 10.1016/j.vaccine.2007.01.064
34. + T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol. (2003) 10: 411-6. Doi: 10.1128/CDLI.10.3.411-416.2003
35. Muhlebach MD. Vaccine platform recombinant measles virus. Virus Genes (2017) 53: 733-40. Doi: 10.1007/s11262-017-1486-3
36. Baldo A, Galanis E, Tangy F, Herman P. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother. (2016) 12: 1102-16. Doi: 10.1080/21645515.2015.1122146
37. Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based Chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. (2015) 15: 519-27. Doi: 10.1016/S1473-3099(15)70043-5
38. Letchworth GJ, Rodriguez LL, Del Cbarrera J. Vesicular stomatitis. Vet J. (1999) 157: 239-60. Doi: 10.1053/tvjl.1998.0303
39. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA. (1995) 92: 4477-81. Doi: 10.1073/pnas.92.10.4477
40. Van Den Pol AN, Davis JN. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol. (2013) 87: 1019-34. Doi: 10.1128/JVI.01106-12
41. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2007) 360: 36-49. Doi: 10.1016/j.virol.2006.10.026
42. Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, et al. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine (2016) 34: 6597-609. Doi: 10.1016/j.vaccine.2016.06.071
43. Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open (2015) 5: e008748. Doi: 10.1136/bmjopen-2015-008748
44. Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine (2015) 33: 5225-34. Doi: 10.1016/j.vaccine.2015.06.075
45. Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine (2013) 31: 1026-33. Doi: 10.1016/j.vaccine.2012.12.042
46. Liebowitz D, Lindbloom JD, Brandl JR, Garg SJ, Tucker SN. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. (2015) 15: 1041-8. Doi: 10.1016/S1473-3099(15)00266-2
47. + T cell responses. Eur J Immunol. (2005) 35: 2532-40. Doi: 10.1002/eji.200535184
48. Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine (2013) 31: 1752-8. Doi: 10.1016/j.vaccine.2013.01.023
49. Venkatraman N, Anagnostou N, Bliss C, Bowyer G, Wright D, Lovgren-Bengtsson K, et al. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M. Vaccine (2017) 35: 6208-17. Doi: 10.1016/j.vaccine.2017.09.028
50. Baldo A, Van Den Akker E, Bergmans HE, Lim F, Pauwels K. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther. (2013) 13: 385-94. Doi: 10.2174/15665232113136660005
51. Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, et al. Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains. Vaccine (2016) 34: 6610-6. Doi: 10.1016/j.vaccine.2016.04.060
52. Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, et al. Adventitious agents and live viral vectored vaccines: considerations for archiving samples of biological materials for retrospective analysis. Vaccine (2016) 34: 6617-25. Doi: 10.1016/j.vaccine.2016.02.015
53. Petricciani J, Sheets R, Griffiths E, Knezevic I. Adventitious agents in viral vaccines: lessons learned from 4 case studies. Biologicals (2014) 42: 223-36. Doi: 10.1016/j.biologicals.2014.07.003
54. Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F. Ebola vaccines in clinical trial: the promising candidates. Hum Vaccin Immunother. (2017) 13: 153-68. Doi: 10.1080/21645515.2016.1225637
55. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 408: 605-9. Doi: 10.1038/35046108
56. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 424: 681-4. Doi: 10.1038/nature01876
57. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. (2006) 3: e177. Doi: 10.1371/journal.pmed.0030177
58. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 29: 304-13. Doi: 10.1016/j.vaccine.2010.10.037
59. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet (2015) 385: 2272-9. Doi: 10.1016/S0140-6736(15)60553-0
60. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. (2014) 20: 1126-9. Doi: 10.1038/nm.3702
61. Ledgerwood JE, Dezure AD, Stanley DA, Coates EE, Novik L, Enama ME, et al. Chimpanzee Adenovirus vector Ebola vaccine. N Engl J Med. (2017) 376: 928-38. Doi: 10.1056/NEJMoa1410863
62. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, et al. A monovalent Chimpanzee Adenovirus Ebola vaccine boosted with MVA. N Engl J Med. (2016) 374: 1635-46. Doi: 10.1056/NEJMoa1411627
63. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. (2016) 16: 31-42. Doi: 10.1016/S1473-3099(15)00362-X
64. Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 15: 1101-12. Doi: 10.1080/14760584.2016.1187566
65. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. (2016) 16: 311-20. Doi: 10.1016/S1473-3099(15)00486-7
66. Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. (2017) 377: 1438-47. Doi: 10.1056/NEJMoa1614067
67. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. (2004) 78: 5458-65. Doi: 10.1128/JVI.78.10.5458-5465.2004
68. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. (2005) 11: 786-90. Doi: 10.1038/nm1258
69. Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science (2015) 349: 739-42. Doi: 10.1126/science.aab3920
70. Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G, Feldmann H. Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in Rhesus Macaques infected With Ebola virus Makona. J Infect Dis. (2016) 214: S360-6. Doi: 10.1093/infdis/jiw218
71. Medaglini D, Siegrist CA. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine. Curr Opin Virol. (2017) 23: 88-94. Doi: 10.1016/j.coviro.2017.03.008
72. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med (2016) 374: 1647-60. Doi: 10.1056/NEJMoa1502924
73. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. (2017) 376: 330-41. Doi: 10.1056/NEJMoa1414216
74. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet (2015) 386: 857-66. Doi: 10.1016/S0140-6736(15)61117-5
75. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet (2017) 389: 505-18. Doi: 10.1016/S0140-6736(16)32621-6
76. Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines (2013) 1: 225-49. Doi: 10.3390/vaccines1030225
77. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 8: 495-500. Doi: 10.1016/S1525-0016(03)00168-0
78. Walters AA, Kinnear E, Shattock RJ, Mcdonald JU, Caproni LJ, Porter N, et al. Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines. Gene Ther (2014) 21: 645-52. Doi: 10.1038/gt.2014.37
79. Lambricht L, Lopes A, Kos S, Sersa G, Preat V, Vandermeulen G. Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv. (2016) 13: 295-310. Doi: 10.1517/17425247.2016.1121990
80. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. (2011) 23: 421-9. Doi: 10.1016/j.coi.2011.03.008
81. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. (2005) 175: 633-9. Doi: 10.4049/jimmunol.175.2.633
82. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines (2016) 15: 313-29. Doi: 10.1586/14760584.2016.1124762
83. + T cells after gene gun immunization. J Exp Med. (1998) 188: 1075-82. Doi: 10.1084/jem.188.6.1075
84. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology (2000) 43: 273-81. Doi: 10.1159/000053994
85. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. (1997) 3: 362-71.
86. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol. (1997) 159: 11-4.
87. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. (1996) 184: 1555-60. Doi: 10.1084/jem.184.4.1555
88. Armengol G, Ruiz LM, Orduz S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol Biotechnol. (2004) 27: 109-18. Doi: 10.1385/MB: 27: 2: 109
89. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. (2004) 11: 711-21. Doi: 10.1038/sj.gt.3302213
90. Schalk JA, Mooi FR, Berbers GA, Van Aerts LA, Ovelgonne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin. (2006) 2: 45-53. Doi: 10.4161/hv.2.2.2620
91. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science (1990) 247: 1465-8. Doi: 10.1126/science.1690918
92. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, et al. Immunization for Ebola virus infection. Nat Med. (1998) 4: 37-42. Doi: 10.1038/nm0198-037
93. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology (1998) 246: 134-44. Doi: 10.1006/viro.1998.9176
94. Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from Ebola and Marburg virus challenge. Hum Vaccin Immunother. (2012) 8: 1703-6. Doi: 10.4161/hv.21873
95. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. (2006) 13: 1267-77. Doi: 10.1128/CVI.00162-06
96. Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. (2015) 211: 549-57. Doi: 10.1093/infdis/jiu511
97. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet (2015) 385: 1545-54. Doi: 10.1016/S0140-6736(14)62385-0
98. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin. (2007) 3: 157-64. Doi: 10.4161/hv.3.5.4175
99. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis. (2008) 197: 1643-52. Doi: 10.1086/588431
100. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. (2009) 360: 2605-15. Doi: 10.1056/NEJMoa0903810
101. Crank MC, Gordon IJ, Yamshchikov GV, Sitar S, Hu Z, Enama ME, et al. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS ONE (2015) 10: e0123969. Doi: 10.1371/journal.pone.0123969
102. Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines (2016) 1: 16021. Doi: 10.1038/npjvaccines.2016.21
103. Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine-preliminary report. N Engl J Med. (2017) doi: 10.1056/NEJMoa1708120. [Epub ahead of print].
104. Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet (2018) 391: 552-62. Doi: 10.1016/S0140-6736(17)33105-7
105. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. (2012) 9: 1319-30. Doi: 10.4161/rna.22269
106. Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol. (2017) 1499: 109-21. Doi: 10.1007/978-1-4939-6481-9-6
107. Pardi N, Hogan MJ, Porter FW, Weissman D. MRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov. (2018) 17: 261-79. Doi: 10.1038/nrd.2017.243
108. Pardi N, Muramatsu H, Weissman D, Kariko K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol. (2013) 969: 29-42. Doi: 10.1007/978-1-62703-260-5-2
109. Weissman D, Pardi N, Muramatsu H, Kariko K. HPLC purification of in vitro transcribed long RNA. Methods Mol Biol. (2013) 969: 43-54. Doi: 10.1007/978-1-62703-260-5-3
110. Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. (2011) 39: e142. Doi: 10.1093/nar/gkr695
111. Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. (1991) 5: 2108-16. Doi: 10.1101/gad.5.11.2108
112. Parker R, Song H. The enzymes and control of eukaryotic mRNA turnover. Nat Struct Mol Biol. (2004) 11: 121-7. Doi: 10.1038/nsmb724
113. Yamashita A, Chang TC, Yamashita Y, Zhu W, Zhong Z, Chen CY, et al. Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. Nat Struct Mol Biol. (2005) 12: 1054-63. Doi: 10.1038/nsmb1016
114. Ramanathan A, Robb GB, Chan SH. MRNA capping: biological functions and applications. Nucleic Acids Res. (2016) 44: 7511-26. Doi: 10.1093/nar/gkw551
115. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA (2001) 7: 1486-95.
116. Venkatesan S, Gershowitz A, Moss B. Modification of the 5' end of mRNA. Association of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from vaccinia virus. J Biol Chem. (1980) 255, 903-908.
117. Ross J, Sullivan TD. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood (1985) 66: 1149-54.
118. Gallie DR, Tanguay RL, Leathers V. The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation. Gene (1995) 165: 233-8. Doi: 10.1016/0378-1119(95)00521-7
119. Kariko K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. (2012) 20: 948-53. Doi: 10.1038/mt.2012.7
120. Vivinus S, Baulande S, Van Zanten M, Campbell F, Topley P, Ellis JH, et al. An element within the 5' untranslated region of human Hsp70 mRNA which acts as a general enhancer of mRNA translation. Eur J Biochem. (2001) 268: 1908-17. Doi: 10.1046/j.1432-1327.2001.02064.x
121. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 108: 4009-17. Doi: 10.1182/blood-2006-04-015024
122. Zohra FT, Chowdhury EH, Tada S, Hoshiba T, Akaike T. Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection. Biochem Biophys Res Commun. (2007) 358: 373-8. Doi: 10.1016/j.bbrc.2007.04.059
123. Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. (2015) 23: 1456-64. Doi: 10.1038/mt.2015.103
124. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. (2012) 30: 1210-6. Doi: 10.1038/nbt.2436
125. Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. (2006) 4: e180. Doi: 10.1371/journal.pbio.0040180
126. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. (2004) 22: 346-53. Doi: 10.1016/j.tibtech.2004.04.006
127. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. (2008) 16: 1833-40. Doi: 10.1038/mt.2008.200
128. Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, et al. Self-amplifying mRNA vaccines. Adv Genet. (2015) 89: 179-233. Doi: 10.1016/bs.adgen.2014.10.005
129. Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. (2003) 77: 10394-403. Doi: 10.1128/JVI.77.19.10394-10403.2003
130. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. (2012) 109: 14604-9. Doi: 10.1073/pnas.1209367109
131. Iavarone C, O'hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines (2017) 16: 871-81. Doi: 10.1080/14760584.2017.1355245
132. Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. (2018) 26: 446-55. Doi: 10.1016/j.ymthe.2017.11.017
133. Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines. Hum Vaccin Immunother. (2013) 9: 2263-76. Doi: 10.4161/hv.25181
134. Lundstrom K. Replicon RNA viral vectors as vaccines. Vaccines (Basel) (2016) 4: E39. Doi: 10.3390/vaccines4040039
135. Selmi A, Vascotto F, Kautz-Neu K, Tureci O, Sahin U, Von Stebut E, et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol Immunother. (2016) 65: 1075-83. Doi: 10.1007/s00262-016-1869-7
136. Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol. (2000) 114: 632-6. Doi: 10.1046/j.1523-1747.2000.00929.x
137. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. (2004) 61: 2418-24. Doi: 10.1007/s00018-004-4255-0
138. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. (2010) 70: 9031-40. Doi: 10.1158/0008-5472.CAN-10-0699
139. Bialkowski L, Van Weijnen A, Van Der Jeught K, Renmans D, Daszkiewicz L, Heirman C, et al. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep. (2016) 6: 22509. Doi: 10.1038/srep22509
140. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547: 222-6. Doi: 10.1038/nature23003
141. Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines (2017) 2: 29. Doi: 10.1038/s41541-017-0032-6
142. Qiu P, Ziegelhoffer P, Sun J, Yang NS. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. (1996) 3: 262-8.
143. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother. (2006) 55: 246-53. Doi: 10.1007/s00262-005-0042-5
144. Aberle JH, Aberle SW, Kofler RM, Mandl CW. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J Virol (2005) 79: 15107-13. Doi: 10.1128/JVI.79.24.15107-15113.2005
145. Kofler RM, Aberle JH, Aberle SW, Allison SL, Heinz FX, Mandl CW. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci USA. (2004) 101: 1951-6. Doi: 10.1073/pnas.0307145101
146. Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE (2012) 7: e29732. Doi: 10.1371/journal.pone.0029732
147. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol. (2005) 35: 1557-66. Doi: 10.1002/eji.200425656
148. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. (2011) 34: 1-15. Doi: 10.1097/CJI.0b013e3181f7dbe8
149. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. (2012) 14: 428-39. Doi: 10.1002/jgm.2605
150. Kowalczyk A, Doener F, Zanzinger K, Noth J, Baumhof P, Fotin-Mleczek M, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine (2016) 34: 3882-93. Doi: 10.1016/j.vaccine.2016.05.046
151. Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, Kramps T, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. (2016) 10: e0004746. Doi: 10.1371/journal.pntd.0004746
152. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet (2017) 390: 1511-20. Doi: 10.1016/S0140-6736(17)31665-3
153. Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release (2016) 240: 227-34. Doi: 10.1016/j.jconrel.2015.12.032
154. Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. (2017) 24: 133-43. Doi: 10.1038/gt.2017.5
155. Reichmuth AM, Oberli MA, Jeklenec A, Langer R, Blankschtein D. MRNA vaccine delivery using lipid nanoparticles. Ther Deliv. (2016) 7: 319-34. Doi: 10.4155/tde-2016-0006
156. Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines (2015) 14: 221-34. Doi: 10.1586/14760584.2015.986104
157. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. (2013) 12: 967-77. Doi: 10.1038/nmat3765
158. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, Demaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature (2017) 543: 248-51. Doi: 10.1038/nature21428
159. Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. (2017) 25: 1316-27. Doi: 10.1016/j.ymthe.2017.03.035
160. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. (2010) 18: 1357-64. Doi: 10.1038/mt.2010.85
161. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release (2015) 217: 345-51. Doi: 10.1016/j.jconrel.2015.08.007
162. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell (2017) 168: 1114-25.e10. Doi: 10.1016/j.cell.2017.02.017
163. Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell (2017) 170: 273-83.e12. Doi: 10.1016/j.cell.2017.06.040
164. Chen N, Xia P, Li S, Zhang T, Wang TT, Zhu J. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life (2017) 69: 297-304. Doi: 10.1002/iub.1625
165. Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. (2017) 15: 1. Doi: 10.1186/s12967-016-1111-6
166. Lazzaro S, Giovani C, Mangiavacchi S, Magini D, Maione D, Baudner B, et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology (2015) 146: 312-26. Doi: 10.1111/imm.12505
167. Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Rohss J, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA Vaccine Administration in Rhesus Macaques. Mol Ther. (2017) 25: 2635-47. Doi: 10.1016/j.ymthe.2017.08.006
168. Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, et al. Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. (2017) 8: 1539. Doi: 10.3389/fimmu.2017.01539
169. Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol. (2017) 198: 4012-24. Doi: 10.4049/jimmunol.1601877
170. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release (2015) 217: 337-44. Doi: 10.1016/j.jconrel.2015.08.051
171. Pinschewer DD. Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly (2017) 147: w14465. Doi: 10.4414/smw.2017.14465
172. De Bruyn G. Cofactors that may influence vaccine responses. Curr Opin HIV AIDS (2010) 5: 404-8. Doi: 10.1097/COH.0b013e32833d1fca
173. Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol. (2016) 90: 332-44. Doi: 10.1128/JVI.01786-15
174. Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. (2017) 8: 14630. Doi: 10.1038/ncomms14630
175. Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis. (2018) 217: 451-5. Doi: 10.1093/infdis/jix592
176. Wang M, Jokinen J, Tretyakova I, Pushko P, Lukashevich IS. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. Vaccine (2018) 36: 683-90. Doi: 10.1016/j.vaccine.2017.12.046
177. Magini D, Giovani C, Mangiavacchi S, Maccari S, Cecchi R, Ulmer JB, et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE (2016) 11: e0161193. Doi: 10.1371/journal.pone.0161193
178. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. (2013) 2: e52. Doi: 10.1038/emi.2013.54
179. Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis. (2015) 211: 947-55. Doi: 10.1093/infdis/jiu522
180. Chahal JS, Khan OF, Cooper CL, Mcpartlan JS, Tsosie JK, Tilley LD, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA. (2016) 113: E4133-4142. Doi: 10.1073/pnas.1600299113
181. + T cell responses in a mouse model. Sci Rep. (2017) 7: 252. Doi: 10.1038/s41598-017-00193-w